Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MetaVia Inc.NRBO · Entity 7947 | Director · 10% owner | July 27, 2023 | July 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MetaVia Inc.
Report date July 27, 2023 · Filed July 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 88,959 |
Reported balance
After 2023-07-27 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-07-27 · Grant · Acquired 87,500 · Balance 88,959 F1: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F2: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service. F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 101,459 |
Reported balance
After 2023-07-27 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-07-27 · Grant · Acquired 12,500 · Balance 101,459 F1: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F4: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. |
| Common StockSEC Table I · non-derivative | IndirectHeld by E&Investment Inc. | 4,671 |
Reported balance
Holding disclosure · report date 2023-07-27 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,671 F5: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by The E&Healthcare Investment Fund II | 96,351 |
Reported balance
Holding disclosure · report date 2023-07-27 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 96,351 F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. F5: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by The E&Healthcare Investment Fund No. 6 | 37,373 |
Reported balance
Holding disclosure · report date 2023-07-27 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 37,373 F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. F5: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectHeld by The E&Healthcare Investment Fund No. 7 | 62,159 |
Reported balance
Holding disclosure · report date 2023-07-27 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 62,159 F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. F5: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan.
F2: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service.
F3: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock.
F4: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service.
F5: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2023 Filed Jul 28, 2023 10:08 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084965 · tm2321997-6_4seq1.xml · nonDerivative · entry 2 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,459 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F4 · shares: Vests on the earlier of July 27, 2024 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Read SEC document |
| July 27, 2023 Filed Jul 28, 2023 10:08 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 87,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084965 · tm2321997-6_4seq1.xml · nonDerivative · entry 1 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,959 F1 · shares: Represents a grant of restricted stock units ("RSUs") issued to the reporting person under the Issuer's 2022 Equity Incentive Plan. F2 · shares: 50% of the RSUs vested immediately, and the remainder will vest in two equal installments on each subsequent anniversary of the date of grant, subject to continuing service. F3 · balance_after: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. Read SEC document |
| July 26, 2022 Filed Jul 28, 2022 20:03 UTC | MetaVia Inc. NRBO · Entity 7947 | OtherCommon Stock | 1,445,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-083645 · tm2222080-1_4seq1.xml · nonDerivative · entry 1 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The E&Healthcare Investment Fund II Disclosed balance after: 2,890,533 F1 · kind: E&Healthcare Investment Fund II distributed 1,445,267 shares to its partners on a pro rata basis, for no consideration. F2 · ownership.nature: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| July 26, 2022 Filed Jul 28, 2023 10:02 UTC Amendment | MetaVia Inc. NRBO · Entity 7947 | OtherCommon Stock | 4,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-084928 · tm2321997-7_4aseq1.xml · nonDerivative · entry 1 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · Held by E&Investment Inc. Disclosed balance after: 4,671 F1 · security: This amendment is being filed to add the acquisition of 4,671 shares by E&Investment Inc., which was inadvertently left off the original Form 4. F2 · kind: E&Investment Inc. received a pro rata distribution from E&Healthcare Investment Fund II, of which the reporting person is a limited partner, for no consideration. F3 · shares: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. F3 · balance_after: The share amount has been adjusted to reflect the reverse stock split effective on September 12, 2022 whereby each thirty shares issued and outstanding prior to the split were combined and converted into one share of common stock. F4 · ownership.nature: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:14 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNonstatutory Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.47 | $0.00 |
DisclosureSEC source: 0001104659-22-070532 · tm2218193-6_4seq1.xml · derivative · entry 1 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: Vests on the earlier of June 9, 2023 or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to continuing service. Read SEC document |
| January 13, 2020 Filed Jan 16, 2020 00:13 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNon-qualified stock option (right to buy) · Derivative | 60,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0001683168-20-000161 · ownership.xml · derivative · entry 1 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-01-12 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments beginning on 2/13/2020, such that the option will be fully vested on the third anniversary of the date of grant. Read SEC document |
| December 30, 2019 Filed Jan 3, 2020 02:52 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 1,864,799 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-000014 · ownership.xml · nonDerivative · entry 3 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The E&Healthcare Investment Fund No. 7 Disclosed balance after: 1,864,799 F3 · price: Received in connection with the closing of the Merger in exchange for 1,500,000 shares of common stock issued upon the conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 131,353 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund No. 7. F4 · price: In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock. F5 · ownership.nature: Ms. Kim is the Chief Executive Officer of E&I Investment. E&Investment is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and has voting power over the shares held by The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7. Ms. Kim is the Chief Executive Officer of E&Investment, and as such has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| December 30, 2019 Filed Jan 3, 2020 02:52 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 1,121,190 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-000014 · ownership.xml · nonDerivative · entry 2 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The E&Healthcare Investment Fund No. 6 Disclosed balance after: 1,121,190 F2 · price: Received in connection with the closing of the Merger in exchange for 900,000 shares of common stock issued upon conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 80,833 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund No. 6. F4 · price: In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock. F5 · ownership.nature: Ms. Kim is the Chief Executive Officer of E&I Investment. E&Investment is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and has voting power over the shares held by The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7. Ms. Kim is the Chief Executive Officer of E&Investment, and as such has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| December 30, 2019 Filed Jan 3, 2020 02:52 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantCommon Stock | 4,335,800 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001683168-20-000014 · ownership.xml · nonDerivative · entry 1 Kim Na Yeon · CIK 0001794779 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The E&Healthcare Investment Fund II Disclosed balance after: 4,335,800 F1 · price: Received in connection with the closing of the merger of GR Merger Sub Inc., a wholly-owned subsidiary of the Issuer, with and into NeuroBo Therapeutics, Inc. (formerly NeuroBo Pharmaceuticals, Inc.) ("NeuroBo") on December 30, 2019 (the "Merger"), in exchange for 3,500,000 shares of common stock issued upon the conversion of Series A preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 293,019 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund II. F4 · price: In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock. F5 · ownership.nature: Ms. Kim is the Chief Executive Officer of E&I Investment. E&Investment is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and has voting power over the shares held by The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7. Ms. Kim is the Chief Executive Officer of E&Investment, and as such has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.